0001140361-24-030718.txt : 20240620 0001140361-24-030718.hdr.sgml : 20240620 20240620160210 ACCESSION NUMBER: 0001140361-24-030718 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240613 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001281895 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36829 FILM NUMBER: 241056132 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: 646-440-9100 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20040226 8-K 1 ef20031374_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
June 13, 2024

Rocket Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
  
001-36829
  
04-3475813
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)

9 Cedarbrook Drive
Cranbury, NJ 08512
(Address of principal executive offices, including zip code)

(646) 440-9100
(Registrant’s telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common stock, $0.01 par value
  
RCKT
  
The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The 2024 Annual Meeting of Stockholders of Rocket Pharmaceuticals, Inc. (the “Company”) was held on June 13, 2024 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved and adopted an Amendment to the Company’s Seventh Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 120,000,000 shares to 180,000,000 shares (the “Charter Amendment”). Following such approval, the Charter Amendment was filed with the Secretary of State of the State of Delaware and became effective on June 20, 2024.

This description is a summary of the Charter Amendment and is qualified in its entirety by reference to the description of the Charter Amendment under the heading “Proposal 4 – Approval of Increase in Number of Authorized Shares of Common Stock” set forth in the Company’s Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2024 (the “2024 Proxy Statement”), and the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 5.07.
Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, there were present, in person or by proxy, holders of 79,809,770 shares of common stock, or approximately 87.95% of the total outstanding shares eligible to be voted. The holders present voted on the four proposals presented at the Annual Meeting as follows.

Proposal One - Election of Directors

The Company’s stockholders approved the election of ten directors to the Company’s Board of Directors (“Board”) by the following votes:

Nominee
Votes For
Votes Withheld
Broker Non-Votes
Elisabeth Björk, M.D., Ph.D.
67,603,904
4,348,329
7,857,537
Carsten Boess
71,383,452
568,781
7,857,537
Pedro Granadillo
51,458,742
20,493,491
7,857,537
Gotham Makker, M.D.
71,537,718
414,515
7,857,537
Fady Malik, M.D., Ph.D.
71,706,448
245,785
7,857,537
Gaurav Shah, M.D.
71,555,239
396,994
7,857,537
David P. Southwell
71,650,603
301,630
7,857,537
Roderick Wong, M.D.
71,278,861
673,372
7,857,537
R. Keith Woods
69,222,478
2,729,755
7,857,537
Naveen Yalamanchi, M.D.
63,231,665
8,720,568
7,857,537

Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm

The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2024 by the following votes:

Votes For
  
Votes Against
  
Abstentions
79,704,801
  
88,793
  
16,176

Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers

The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2024 Proxy Statement pursuant to Section 14A of the Exchange Act, including the Compensation Discussion and Analysis, the Summary Compensation Table, and the narrative disclosures that accompany the compensation tables. The final votes were:

Votes For
  
Votes Against
  
Abstentions
  
Broker Non-Votes
70,707,935
  
1,134,308
  
109,990
  
7,857,537

Proposal Four - Approval of Increase in Number of Authorized Shares of Common Stock

The Company’s stockholders approved an Amendment to the Company’s Seventh Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 120,000,000 shares to 180,000,000 shares by the following votes:

Votes For
  
Votes Against
  
Abstentions
  
Broker Non-Votes
79,449,783
  
294,948
  
65,039
  
0

Item 9.01.
Financial Statements and Exhibits.

(d)
Exhibits.

Exhibit
No.
  
Description
 
Certificate of Amendment to the Company’s Seventh Amended and Restated Certificate of Incorporation, effective June 20, 2024
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Rocket Pharmaceuticals, Inc.
     
Date: June 20, 2024
By:
/s/ Gaurav Shah, MD
   
Gaurav Shah, MD
   
Chief Executive Officer and Director


EX-3.1 2 ef20031374_ex3-1.htm EXHIBIT 3.1
Exhibit 3.1

CERTIFICATE OF AMENDMENT OF
SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF
ROCKET PHARMACEUTICALS, INC.
PURSUANT TO SECTION 242 OF THE
GENERAL CORPORATION LAW OF THE STATE OF DELAWARE
 
Rocket Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), hereby certifies as follows:
 
The Board of Directors of the Corporation (the “Board of Directors”), pursuant to Section 242 of the Delaware General Corporation Law (“DGCL”), has duly adopted a resolution setting forth the following proposed amendment (the “Amendment”) to the Corporation’s seventh amended and restated certificate of incorporation as currently in effect (the “Certificate of Incorporation”) and declared such amendment advisable, and the stockholders of the Corporation have duly approved and adopted the Amendment at the annual meeting of stockholders called and held upon notice in accordance with Section 222 and Section 242 of the DGCL. Accordingly, the Amendment has been duly adopted in accordance with Section 242 of the DGCL.
 
In order to effect such proposed amendment, ARTICLE IV of the Certificate of Incorporation is hereby amended by deleting the first paragraph of Article IV in its entirety and inserting the following paragraph in lieu thereof:

“The total number of shares of capital stock which the Corporation shall have authority to issue is One Hundred Eighty Five Million (185,000,000), of which (i) One Hundred Eighty Million (180,000,000) shares shall be a class designated as common stock, par value $0.01 per share (the “Common Stock”), and (ii) Five Million (5,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.001 per share (the “Undesignated Preferred Stock”).”

IN WITNESS WHEREOF, this Certificate of Amendment has been executed by a duly authorized officer of the Corporation on this 20th day of June, 2024.
 
 
Rocket Pharmaceuticals, Inc.
    
   By:  /s/ Gaurav Shah
   
Gaurav Shah
   
President and Chief Executive Officer

 
 EX-101.SCH 3 rckt-20240613.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rckt-20240613_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 rckt-20240613_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 13, 2024
Current Fiscal Year End Date --12-31
Entity File Number 001-36829
Entity Registrant Name Rocket Pharmaceuticals, Inc.
Entity Central Index Key 0001281895
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 04-3475813
Entity Address, Address Line One 9 Cedarbrook Drive
Entity Address, City or Town Cranbury
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08512
City Area Code 646
Local Phone Number 440-9100
Title of 12(b) Security Common stock, $0.01 par value
Trading Symbol RCKT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $2 U%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !$@-18^6/K1>T K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)TUE#Z&;B^))07!!\1:2V=U@\X=DI-VWMZV[740?P&-F?OGF M&YC.)&EBQN<<$V9R6&Y&WXM23XDP-?TW3,Q\@:?.A M#PB"\PUX)&TU:9B!55J)3'762)-14\QGO#4K/GWF?H%9 ]BCQT %FKH!IN:) MZ33V'5P!,XPP^_)=0+L2E^J?V*4#[)P'MZ?%G6K5PH MI(/!Z5=QDDX)M^PR^;6]N]\],"6XN*WXIA)\)[CD0O+V?7;]X7<5]M&ZO?O' MQA=!U<&ONU!?4$L#!!0 ( $2 U%B97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M1(#46-!%*8]P! +1$ !@ !X;"]W;W)KDSC50V=C3';MNCK<\(3I2YGQ%'Y9 M294P TVU=G6F.(N*3DGL^I[7=1,F4FQU8)./X]B#KE.VW'X^LW M]?MB\#"8)=-\(N-O(C*;H=-S2,17+(_-3&Y_XXG^F[T> G'4H>V=Z. ?.O@%]_Y%!>4M,VPT4')+E'T:U.Q%,=2B M-\")U,[*W"CX54 _,[J580Y!-H2E$;E+C3 [\I#N9QNB-G -O,0^ZH8'P9N] MH']"\&.>7A+:OB"^YP??=W>!K03T2T"_T&N?T)O(%Z[(W^.E-@JF\)\ZHKU" M4*]@\_I:9RSD0P<25W/UPIW13S_0KOA7 Q2[C=7!X]U[K$8$( M2H@ 51D#0510W,=L74>!]U^Q6'.$HU-R=,X+QI0K(6U"1032LC8NN%*91DUY MU"W1NJC@)%>J")#0(8O)GYPI% ]7:[6HWVI3A.NJY+I"E0YK[E[$G#SER9*K M.AIGZ/]OH=!(MZE9]Z MYX#!,*7*I"I<](+,#:09D8I,9 [$ "ZCVJ VJ-_>89!'ID_/@5RP5_(000C% M"F:GJ)*G4[!!T@M:[>"JTZ-MC+!R?8J:]AOA.(K LB%M#A?D$SQ'OJ3UL<,E M^Y M$5-+!5L$&[BBU^M0'V.K M2@5MJ!4%&6QR3Z/@ MV@BX%4M8'BQOY)VEHUW<@4*PX-(D'@M?K4\S"BJCI0 MW-87PD"ADBM"_9^7OY Y#W,%T:K%PI4F,DG <&"'&SY?D!^]2X^2#(KR"XMS M=&56)8+BSKY0+!+IFLQWR5+&M8BXP&SRN,"VL%51\'';?@L3N7L--RQ=\Y-% MM4'H:3R_'7_%F*H:X)]5 ^X2KM8V2A] P6P@XY.,I;43VB#8M(GTC[;\N%-_ M@U@9GEJ6)$\/I4G7(N%"C4B5R_NX+<]E+$)A;* ^@XG+:E5O$@UZC625L?NX#?^/[$'K',@: 7'9DX#N MT>'7_I'PF=E\UB3F*Q#R+J] 5^W/YON&D5EQ'EY* Z?KXG+#&;#9!^#WE93F MK6&/V.4_)*/_ %!+ P04 " !$@-18GZ ;\+$" #B# #0 'AL+W-T M>6QEO%DN7/Z MZZ>S;"=I=67=A['-HN M6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2 MK"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP( M&K XU7=>&18/QA<0&>7= MJ?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N- M9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W] MK;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LU MF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ> MDO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A M'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/ M9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@> MF*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%' M, ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " !$@-18EXJ[', 3 M @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/ MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%" MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( $2 U%@< M.&7J/P$ #P" / >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+ M5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U( MA:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU M$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#& M;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+8864N-_H^8UH/($L#UW+ M\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0: MFZ15,!X*/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W\!J-'[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):B MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% M @ 1(#46&60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9-- M3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/ MGI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3 M>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+ES MT&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JH MO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-( M9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX: M?^:+X3]>?P%02P$"% ,4 " !$@-18!T%-8H$ "Q $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( $2 U%CY8^M% M[0 "L" 1 " :\ !D;V-0&UL4$L! A0#% @ 1(#46-!%*8]P! +1$ M !@ ("!# @ 'AL+W=O,1 !X;"]? M7!E&UL4$L% 3!@ ) D /@( !(4 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://rocketpharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20031374_8k.htm rckt-20240613.xsd rckt-20240613_lab.xml rckt-20240613_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20031374_8k.htm": { "nsprefix": "rckt", "nsuri": "http://rocketpharma.com/20240613", "dts": { "inline": { "local": [ "ef20031374_8k.htm" ] }, "schema": { "local": [ "rckt-20240613.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "rckt-20240613_lab.xml" ] }, "presentationLink": { "local": [ "rckt-20240613_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://rocketpharma.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240613to20240613", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20031374_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240613to20240613", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20031374_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://rocketpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001140361-24-030718-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-030718-xbrl.zip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end XML 17 ef20031374_8k_htm.xml IDEA: XBRL DOCUMENT 0001281895 2024-06-13 2024-06-13 false --12-31 0001281895 8-K 2024-06-13 Rocket Pharmaceuticals, Inc. DE 001-36829 04-3475813 9 Cedarbrook Drive Cranbury NJ 08512 646 440-9100 false false false false Common stock, $0.01 par value RCKT NASDAQ false